2 – 5 PM CDT Session: Experimental and Molecular Therapeutics – Degraders and Glues 1 Location: McCormick Place Convention Center, Poster Section 18, Poster Board 9 Abstract 4367 – ERAS-4001 ...
SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies ...
Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE ...
Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback